-$0.89 EPS Expected for Aerie Pharmaceuticals (AERI) This Quarter

Equities analysts predict that Aerie Pharmaceuticals (NASDAQ:AERI) will report earnings of ($0.89) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Aerie Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.81) and the lowest estimate coming in at ($0.96). Aerie Pharmaceuticals reported earnings per share of ($0.62) during the same quarter last year, which would suggest a negative year-over-year growth rate of 43.5%. The company is scheduled to report its next earnings results on Tuesday, May 1st.

According to Zacks, analysts expect that Aerie Pharmaceuticals will report full year earnings of ($3.57) per share for the current financial year, with EPS estimates ranging from ($3.62) to ($3.52). For the next year, analysts expect that the company will post earnings of ($1.65) per share, with EPS estimates ranging from ($2.15) to ($0.84). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Aerie Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, February 28th. The company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.17).



AERI has been the topic of a number of recent research reports. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. HC Wainwright began coverage on Aerie Pharmaceuticals in a research report on Friday, February 16th. They issued a “buy” rating and a $78.00 price target for the company. Mizuho reaffirmed a “buy” rating and issued a $87.00 price target on shares of Aerie Pharmaceuticals in a research report on Monday, January 29th. Canaccord Genuity boosted their price target on Aerie Pharmaceuticals from $73.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Finally, BidaskClub cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $78.75.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. QS Investors LLC acquired a new position in shares of Aerie Pharmaceuticals during the 4th quarter worth about $125,000. Public Employees Retirement Association of Colorado acquired a new position in shares of Aerie Pharmaceuticals during the 4th quarter worth about $176,000. Great West Life Assurance Co. Can lifted its position in shares of Aerie Pharmaceuticals by 65.0% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock worth $204,000 after purchasing an additional 1,639 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. acquired a new position in shares of Aerie Pharmaceuticals during the 3rd quarter worth about $204,000. Finally, GSA Capital Partners LLP lifted its position in shares of Aerie Pharmaceuticals by 31.3% during the 3rd quarter. GSA Capital Partners LLP now owns 6,444 shares of the company’s stock worth $313,000 after purchasing an additional 1,538 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

NASDAQ AERI traded down $0.55 on Wednesday, reaching $54.60. The stock had a trading volume of 135,484 shares, compared to its average volume of 349,904. The company has a debt-to-equity ratio of 0.91, a current ratio of 10.09 and a quick ratio of 10.09. Aerie Pharmaceuticals has a 1 year low of $38.14 and a 1 year high of $66.60. The company has a market capitalization of $2,097.07, a P/E ratio of -16.20 and a beta of 0.95.

ILLEGAL ACTIVITY WARNING: “-$0.89 EPS Expected for Aerie Pharmaceuticals (AERI) This Quarter” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://stocknewstimes.com/2018/04/25/0-89-eps-expected-for-aerie-pharmaceuticals-aeri-this-quarter.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply